Randox Myoglobin Assay 의 리콜

Recall

RC-2017-RN-00340-1

Class II

2017-03-10

Australia

DHTGA

https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2017-RN-00340-1

Randox has confirmed a change in recovery with regards to myoglobin in the lots of the liquid cardiac control listed above for the randox immunoturbidimetric method. internal testing of the affected lots has shown an increased rate of degradation for myoglobin only. new targets and control ranges have therefore been assigned for the randox immunoturbidimetric method. recovery of myoglobin for other methods quoted in the ifu has not been confirmed. customers using methods other than the randox immunoturbidimetric method should review their running iqc mean for a shift in trend which may indicate a review of the control range is required.Iqc that is reported as out of range could lead to a delay in reporting myoglobin results. since serum myoglobin is not typically used in isolation for diagnosing cardiac injury a delay in reporting these results should not pose a serious risk to health.

Users are notified to remove the existing IFU from all unused stock and replace it with the lot specific document provided with the customer letter. Also, users are advised to discuss the contents of customer letter with their Medical Director and review results generated with the affected batches in line with the clinical profile of the patient.